MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $4.
561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational 1 basis and 19.
5 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.
34 per share a year ago and achieved adjusted 3 EPS of $0.70 for the period, compared to $0.55 a year ago.
For the full year 2024, the company generated net sales of $16.747 billion , growing 17.6 percent on a reported basis, 18.
5 percent on an operational 1 basis and 16.4 percent on an organic 2 basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.
853 billion or $1.25 per share, compared to $1.570 billion or $1.
07 per share a year ago, and delivered full year adjusted 3 EPS of $2.51 , compared to $2.05 a year ago.
"2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSETM Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions," said Mike Mahoney , chairman and chief executive officer, Boston Scientific. "We have a strong foundation for growth, and I am incredibly grateful for our talented global .
